


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

1FW 1642
PATENT
Attorney Docket No.: 023070-130200US
Client Reference No.: 2001-504-1



TOWNSEND and TOWNSEND and CREW LLP

By: _____

Katherine Parkas

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

CARSON et al.

Application No.: 09/847,102

Filed: May 1, 2001

For: IMMUNOLOGIC COMPOSITIONS
AND METHODS FOR STUDYING
AND TREATING CANCERS
EXPRESSING FRIZZLED ANTIGENS

Examiner: Misook YU, Ph.D.

Art Unit: 1642

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A&B are being called to the attention of the Examiner. Copies of the references are enclosed.

Also enclosed is a copy of the Search/Examination report corresponding to the PCT application.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.


This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.

CERTIFICATION

I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,


Beth L. Kelly
Reg. No. 51,868

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
BLK:klf



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/847,102
				Filing Date	May 1, 2001
				First Named Inventor	Dennis A. CARSON
				Art Unit	1642
				Examiner Name	Misook YU, Ph.D.
Sheet	1	of	1	Attorney Docket Number	023070-130200US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	AA	WO	98/23730		06-04-1998	Olson et al.		<input checked="" type="checkbox"/>
	AB	WO	01/12808	A1	02-22-2001	Senoo et al.		<input checked="" type="checkbox"/>
	AC	WO	01/75067	A2	10-11-2001	Dmanac et al.		<input checked="" type="checkbox"/>
	AD	WO	01/83543	A1	11-08-2001	Ducker		<input checked="" type="checkbox"/>
	AE	WO	02/24733	A2	03-28-2002	Mishra et al.		<input checked="" type="checkbox"/>
	AF	WO	02/059377	A2	08-01-2002	Mack et al.		<input checked="" type="checkbox"/>
	AG	WO	02/088081	A2	07-11-2002	Rhee		<input checked="" type="checkbox"/>
	AH	WO	02/16620	A2	02-28-2002	Andrews et al.		<input checked="" type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	AI	BROWN, "Wnt signaling in breast cancer: have we come full circle?", <u>Breast Cancer Research</u> , 2001, pp. 351-355, Vol. 3(6).	<input checked="" type="checkbox"/>	
	AJ	SAKANAKA et al., "Bridging of β -catenin and glycogen synthase kinase-3 β by Axin and inhibition of β -catenin-mediated transcription", <u>PNAS</u> , 1998, pp. 3020-3023, Vol. 95.	<input checked="" type="checkbox"/>	
	AK	SAMPSON et al., "Negative regulation of the Wnt- β catenin pathway by the transcriptional repressor HBP1", <u>The EMBO Journal</u> , 2001, pp. 4500-4511, Vol. 20(16).	<input checked="" type="checkbox"/>	
	AL	TANNER et al., "BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia", <u>PNAS</u> , 2001, p. 13901-13905, Vol. 98(24).	<input checked="" type="checkbox"/>	
	AM	WEERARATNA et al., "Wnt5a signaling directly affects cells motility and invasion of metastatic melanoma", <u>Cancer Cell</u> , <u>2002</u> , 2002, 279-280, Vol. 1	<input checked="" type="checkbox"/>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.